文献速递糖尿病肥胖与代谢综合征垂体与肾上腺疾病

二甲双胍减少全身性糖皮质激素治疗患者的代谢并发症和炎症:一项随机、双盲、安慰剂对照、概念验证、2期试验

Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-02-25

该研究为英国四家医院开展的随机双盲安慰剂对照2期试验,纳入53例无糖尿病但接受持续泼尼松龙治疗的炎症性疾病患者,二甲双胍组26例、安慰剂组27例,治疗12周。主要终点内脏与皮下脂肪面积比无显著变化(0.11,95%CI -0.02至0.24;p=0.09),但二甲双胍组躯干皮下脂肪减少、代谢及炎症指标改善,肺炎、中重度感染和因不良事件住院均少于安慰剂组,腹泻事件更多。

要点

  • 二甲双胍组与安慰剂组12周内脏与皮下脂肪面积比无显著差异(0.11,95%CI -0.02至0.24;p=0.09)。
  • 二甲双胍组躯干皮下脂肪较安慰剂组减少(-3835 mm²,95%CI -6781至-888;p=0.01)。
  • 二甲双胍组肺炎(1 vs 7;p=0.01)、中重度感染(2 vs 11;p=0.001)及因不良事件住院(1 vs 9;p=0.001)均少于安慰剂组,腹泻事件更多(18 vs 8;p=0.01)。

核心结论

  • 两组间内脏与皮下脂肪面积比未见显著变化,但二甲双胍改善了部分代谢指标和临床结局,需进一步研究。

研究设计与样本

  • 英国四家医院开展的随机、双盲、安慰剂对照、概念验证、2期试验,纳入18至75岁无糖尿病、接受持续泼尼松龙(≥20 mg/天至少4周且随后12周维持≥10 mg/天或等效累积剂量)治疗的炎症性疾病患者53例,按1:1随机分配至二甲双胍组(n=26)或安慰剂组(n=27),按年龄和BMI分层。
  • 二甲双胍和安慰剂口服12周,剂量递增:前5天850 mg/天,接下来5天850 mg每日两次,之后850 mg每日三次。
  • 主要终点为12周内经CT评估的内脏与皮下脂肪面积比的组间差异;主要结局分析采用改良意向性治疗原则;试验注册号ClinicalTrials.gov NCT01319994。

主要发现

  • 2012年7月17日至2014年1月14日评估849例患者资格,53例随机分配;二甲双胍组19例和安慰剂组21例符合主要结局分析条件。
  • 两组糖皮质激素累积剂量相当:二甲双胍组1860 mg泼尼松龙等效剂量(IQR 1060-2810)vs 安慰剂组1770 mg(IQR 1020-2356);p=0.76。
  • 内脏与皮下脂肪面积比组间无变化(0.11,95%CI -0.02至0.24;p=0.09),但二甲双胍组躯干皮下脂肪较安慰剂组减少(-3835 mm²,95%CI -6781至-888;p=0.01)。
  • 二甲双胍组较安慰剂组碳水化合物、脂质、肝脏和骨代谢标志物改善,纤维蛋白溶解、颈动脉内膜中层厚度、炎症参数和疾病活动度临床标志物亦改善。
  • 二甲双胍组肺炎(1例事件 vs 7例;p=0.01)、中重度感染总发生率(2 vs 11;p=0.001)及因不良事件全因住院(1 vs 9;p=0.001)低于安慰剂组;腹泻事件多于安慰剂组(18 vs 8;p=0.01)。

临床怎么用

  • 原文结论认为二甲双胍改善了部分代谢指标和临床结局,但需进一步研究。

局限性

  • 原文结论指出需进一步研究(warrants further investigation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An urgent need to reduce the metabolic side-effects of glucocorticoid overexposure has been recognised, as glucocorticoid excess can lead to Cushing's syndrome, which is associated with high morbidity. We aimed to evaluate the potential of metformin to reverse such effects while sparing the anti-inflammatory benefits of glucocorticoids. METHODS: We did a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial involving four hospitals in the UK. Patients without diabetes were eligible if they were between the ages of 18 and 75 years with an inflammatory disease treated with continuous prednisolone (≥20 mg/day for ≥4 weeks and remaining on ≥10 mg/day for the subsequent 12 weeks, or its cumulative dose-equivalent). Eligible patients were randomly allocated (1:1) to either the metformin or placebo groups, using a computer-generated randomisation table stratified according to age and BMI. Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently. The primary outcome was the between-group difference in visceral-to-subcutaneous fat area ratio over 12 weeks, assessed by CT. Secondary outcomes included changes in metabolic, bone, cardiovascular, and inflammatory parameters over 12 weeks. Our analysis followed a modified intention-to-treat principle for the primary outcome. This study is registered with ClinicalTrials.gov, NCT01319994. FINDINGS: Between July 17, 2012, and Jan 14, 2014, 849 patients were assessed for study eligibility, of which 53 were randomly assigned to receive either metformin (n=26) or placebo (n=27) for 12 weeks. 19 patients in the metformin group and 21 in the placebo group were eligible for the primary outcome analysis. Both groups received an equivalent cumulative dose of glucocorticoids (1860 mg prednisolone-equivalent [IQR 1060-2810] in the metformin group vs 1770 mg [1020-2356] in the placebo group); p=0·76). No change in the visceral-to-subcutaneous fat area ratio between the treatment groups was observed (0·11, 95% CI -0·02 to 0·24; p=0·09), but patients in the metformin group lost truncal subcutaneous fat compared with the placebo group (-3835 mm2, 95% CI -6781 to -888; p=0·01). Improvements in markers of carbohydrate, lipid, liver, and bone metabolism were observed in the metformin group compared with the placebo group. Additionally, those in the metformin group had improved fibrinolysis, carotid intima-media thickness, inflammatory parameters, and clinical markers of disease activity. The frequency of pneumonia (one event in the metformin group vs seven in the placebo group; p=0·01), overall rate of moderate-to-severe infections (two vs 11; p=0·001), and all-cause hospital admissions due to adverse events (one vs nine; p=0·001) were lower in the metformin group than in the placebo group. Patients in the metformin group had more events of diarrhoea than the placebo group (18 events vs eight; p=0·01). INTERPRETATION: No significant changes in the visceral-to-subcutaneous fat area ratio between the treatment groups were observed; however, metformin administration did improve some of the metabolic profile and clinical outcomes for glucocorticoid-treated patients with inflammatory disease, which warrants further investigation. FUNDING: Barts Charity and Merck Serono.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pernicova I, Kelly S, Ajodha S, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol. 2020. PMID: 32109422. doi:10.1016/S2213-8587(20)30021-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。